Welcome to BioMarket Group!

R&D

In this section you will find R&D market research reports and publications. These provide information on the latest products, news, market growth forecasts, data and business opportunities of value to your organization.

Items 1 to 15 of 32 total

per page
Page:
  1. 1
  2. 2
  3. 3

Set Ascending Direction
  1. IL-3 Signaling Pathway in Oncology Drug Pipeline Update

    $2,250.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 257 companies plus partners who are today developing 339 IL-3 pathway targeting drugs in 1225 developmental projects in cancer across 164 different targets. In addition, there are 4 suspended drugs and another 131 drugs where development has been ceased. Learn More

  2. Nucleic Acid Therapies in Oncology Drug Pipeline Update

    $2,250.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 308 companies plus partners who are today developing 381 nucleic acid therapy drugs in 775 developmental projects in cancer across 251 different targets. In addition, there are 9 suspended drugs and another 211 drugs where development has been ceased. Learn More

  3. IL-1 Signaling Pathway in Oncology Drug Pipeline Update

    $1,495.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 111 companies plus partners who are today developing 113 IL-1 pathway targeting drugs in 415 developmental projects in cancer across 96 different targets. In addition, there are 2 suspended drugs and another 55 drugs where development has been ceased. Learn More

  4. B Cell Receptor Signaling Pathway in Oncology Drug Pipeline Update

    $2,250.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 309 companies plus partners who are today developing 424 B cell receptor pathway targeting drugs in 1700 developmental projects in cancer across 198 different targets. In addition, there are 5 suspended drugs and another 154 drugs where development has been ceased. Learn More

  5. Androgen Receptor Signaling Pathway in Oncology Drug Pipeline Update

    $2,250.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 455 companies plus partners who are today developing 569 Androgen Receptor drugs in 1838 developmental projects in cancer across 228 different targets. In addition, there are 2 suspended drugs and another 258 drugs where development has been ceased. Learn More

  6. Breast Cancer Drug Pipeline Update

    $2,250.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 636 companies plus partners who are today developing 706 drugs targeting breast cancer in development. across 469 different targets. In addition, there are 7 suspended drugs and another 242 drugs where development has been ceased. Learn More

  7. Notch Signaling Pathway in Oncology Drug Pipeline Update

    $2,250.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 335 companies plus partners who are today developing 416 Notch pathway targeting drugs in 1497 developmental projects in cancer across 232 different targets. In addition, there are 4 suspended drugs and another 236 drugs where development has been ceased. Learn More

  8. ID Signaling Pathway in Oncology Drug Pipeline Update

    $750.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 117 companies plus partners who are today developing 114 ID pathway targeting drugs in 493 developmental projects in cancer across 104 different targets. In addition, there is 1 suspended drug and another 62 drugs where development has been ceased. Learn More

  9. IL-9 Signaling Pathway in Oncology Drug Pipeline Update

    $1,495.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 83 companies plus partners who are today developing 88 IL-9 pathway targeting drugs in 366 developmental projects in cancer across 67 different targets. In addition, there is 1 suspended drug and another 35 drugs where development has been ceased. Learn More

  10. TNF-Alpha Signaling Pathway in Oncology Drug Pipeline Update

    $2,250.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 534 companies plus partners who are today developing 731 TNF-alpha pathway targeting drugs in 2597 developmental projects in cancer across 286 different targets. In addition, there are 5 suspended drugs and another 313 drugs where development has been ceased. Learn More

  11. IL-6 Signaling Pathway in Oncology Drug Pipeline Update

    $2,250.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 378 companies plus partners who are today developing 467 IL-6 pathway targeting drugs in 1579 developmental projects in cancer across 198 different targets. In addition, there are 2 suspended drugs and another 203 drugs where development has been ceased. Learn More

  12. EGFR1 Signaling Pathway in Oncology Drug Pipeline Update

    $2,250.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 554 companies plus partners who are today developing 852 EGFR1 pathway targeting drugs in 3067 developmental projects in cancer across 295 different targets. In addition, there are 5 suspended drugs and another 379 drugs where development has been ceased. Learn More

  13. IL-4 Signaling Pathway in Oncology Drug Pipeline Update

    $2,250.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 208 companies plus partners who are today developing 274 IL-4 pathway targeting drugs in 988 developmental projects in cancer across 161 different targets. In addition, there are 4 suspended drugs and another 105 drugs where development has been ceased. Learn More

  14. Proteins in Oncology Drug Pipeline Update

    $2,250.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 455 companies plus partners who are today developing 521 protein drugs in 914 developmental projects in cancer across 229 different targets. In addition, there are 2 suspended drugs and another 207 drugs where development has been ceased. Learn More

  15. IL-2 Signaling Pathway in Oncology Drug Pipeline Update

    $2,250.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 344 companies plus partners who are today developing 449 IL-2 pathway targeting drugs in 1619 developmental projects in cancer across 192 different targets. In addition, there are 6 suspended drugs and another 183 drugs where development has been ceased. Learn More

Items 1 to 15 of 32 total

per page
Page:
  1. 1
  2. 2
  3. 3

Set Ascending Direction

R&D

In this section you will find R&D market research reports and publications. These provide information on the latest products, news, market growth forecasts, data and business opportunities of value to your organization.

Items 1 to 15 of 32 total

per page
Page:
  1. 1
  2. 2
  3. 3

Set Ascending Direction
  1. IL-3 Signaling Pathway in Oncology Drug Pipeline Update

    $2,250.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 257 companies plus partners who are today developing 339 IL-3 pathway targeting drugs in 1225 developmental projects in cancer across 164 different targets. In addition, there are 4 suspended drugs and another 131 drugs where development has been ceased. Learn More

  2. Nucleic Acid Therapies in Oncology Drug Pipeline Update

    $2,250.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 308 companies plus partners who are today developing 381 nucleic acid therapy drugs in 775 developmental projects in cancer across 251 different targets. In addition, there are 9 suspended drugs and another 211 drugs where development has been ceased. Learn More

  3. IL-1 Signaling Pathway in Oncology Drug Pipeline Update

    $1,495.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 111 companies plus partners who are today developing 113 IL-1 pathway targeting drugs in 415 developmental projects in cancer across 96 different targets. In addition, there are 2 suspended drugs and another 55 drugs where development has been ceased. Learn More

  4. B Cell Receptor Signaling Pathway in Oncology Drug Pipeline Update

    $2,250.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 309 companies plus partners who are today developing 424 B cell receptor pathway targeting drugs in 1700 developmental projects in cancer across 198 different targets. In addition, there are 5 suspended drugs and another 154 drugs where development has been ceased. Learn More

  5. Androgen Receptor Signaling Pathway in Oncology Drug Pipeline Update

    $2,250.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 455 companies plus partners who are today developing 569 Androgen Receptor drugs in 1838 developmental projects in cancer across 228 different targets. In addition, there are 2 suspended drugs and another 258 drugs where development has been ceased. Learn More

  6. Breast Cancer Drug Pipeline Update

    $2,250.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 636 companies plus partners who are today developing 706 drugs targeting breast cancer in development. across 469 different targets. In addition, there are 7 suspended drugs and another 242 drugs where development has been ceased. Learn More

  7. Notch Signaling Pathway in Oncology Drug Pipeline Update

    $2,250.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 335 companies plus partners who are today developing 416 Notch pathway targeting drugs in 1497 developmental projects in cancer across 232 different targets. In addition, there are 4 suspended drugs and another 236 drugs where development has been ceased. Learn More

  8. ID Signaling Pathway in Oncology Drug Pipeline Update

    $750.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 117 companies plus partners who are today developing 114 ID pathway targeting drugs in 493 developmental projects in cancer across 104 different targets. In addition, there is 1 suspended drug and another 62 drugs where development has been ceased. Learn More

  9. IL-9 Signaling Pathway in Oncology Drug Pipeline Update

    $1,495.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 83 companies plus partners who are today developing 88 IL-9 pathway targeting drugs in 366 developmental projects in cancer across 67 different targets. In addition, there is 1 suspended drug and another 35 drugs where development has been ceased. Learn More

  10. TNF-Alpha Signaling Pathway in Oncology Drug Pipeline Update

    $2,250.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 534 companies plus partners who are today developing 731 TNF-alpha pathway targeting drugs in 2597 developmental projects in cancer across 286 different targets. In addition, there are 5 suspended drugs and another 313 drugs where development has been ceased. Learn More

  11. IL-6 Signaling Pathway in Oncology Drug Pipeline Update

    $2,250.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 378 companies plus partners who are today developing 467 IL-6 pathway targeting drugs in 1579 developmental projects in cancer across 198 different targets. In addition, there are 2 suspended drugs and another 203 drugs where development has been ceased. Learn More

  12. EGFR1 Signaling Pathway in Oncology Drug Pipeline Update

    $2,250.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 554 companies plus partners who are today developing 852 EGFR1 pathway targeting drugs in 3067 developmental projects in cancer across 295 different targets. In addition, there are 5 suspended drugs and another 379 drugs where development has been ceased. Learn More

  13. IL-4 Signaling Pathway in Oncology Drug Pipeline Update

    $2,250.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 208 companies plus partners who are today developing 274 IL-4 pathway targeting drugs in 988 developmental projects in cancer across 161 different targets. In addition, there are 4 suspended drugs and another 105 drugs where development has been ceased. Learn More

  14. Proteins in Oncology Drug Pipeline Update

    $2,250.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 455 companies plus partners who are today developing 521 protein drugs in 914 developmental projects in cancer across 229 different targets. In addition, there are 2 suspended drugs and another 207 drugs where development has been ceased. Learn More

  15. IL-2 Signaling Pathway in Oncology Drug Pipeline Update

    $2,250.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 344 companies plus partners who are today developing 449 IL-2 pathway targeting drugs in 1619 developmental projects in cancer across 192 different targets. In addition, there are 6 suspended drugs and another 183 drugs where development has been ceased. Learn More

Items 1 to 15 of 32 total

per page
Page:
  1. 1
  2. 2
  3. 3

Set Ascending Direction